Market Overview

UPDATE: Cantor Fitzgerald Raises PT on Cubist Pharmaceuticals

Related CBST
Morning Market Losers
Cepheid Forms Pharma Alliance to Fight Antibiotic Resistance - Analyst Blog

In a report published on Wednesday, Cantor Fitzgerald analyst Irina Rivkind raised the price target on Cubist Pharmaceuticals (NASDAQ: CBST) from $50.00 to $65.00 and maintained a Hold rating on the stock.

In the report, Cantor Fitzgerald cited recent announcements by Cubist to acquire Optimer Pharmaceuticals and Trius Therapeutics, stating, "Management estimates that these two new assets combined could add $0.6-1.0B in peak revenues, with minimal incremental SG&A investment."

Cubist Pharmaceuticals closed Tuesday at $57.00.

Posted-In: Cantor Fitzgerald Irina RivkindAnalyst Color Price Target Analyst Ratings

 

Related Articles (CBST)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters